Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma
Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.
Juan Pablo Alderuccio, MD, assistant professor of Medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma.
In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized vs advanced disease and novel emerging strategies clinicians who are practicing in the community should be aware of.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Expert Commentary on the Product Profile of Umbralisib for Lymphoma
October 17th 2021In an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.
FDA Grants Accelerated Approval to Zanubrutinib for Relapsed/Refractory MZL
September 15th 2021Based on response data from the phase 2 MAGNOLIA trial, the FDA has granted accelerated approval to the Bruton tyrosine kinase inhibitor zanubrutinib to treat patients with relapsed/refractory marginal zone lymphoma.
